SBH
CORT icon

Segall Bryant & Hamill’s Corcept Therapeutics CORT Stock Holding History

Segall Bryant & Hamill’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,393
Closed -$1.42M – 586
2025
Q2 		$1.42M Sell
19,393
-1,371
-7% -$99.4K 0.02% 474
2025
Q1 		$2.37M Sell
20,764
-1,020
-5% -$62.1K 0.04% 405
2024
Q4 		$1.1M Buy
+21,784
New +$1.14M 0.02% 503

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Segall Bryant & Hamill's CORT Position: Q3 2025 in Review

Segall Bryant & Hamill sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 19,393 shares — an estimated $1.42M sold.

Segall Bryant & Hamill first reported a position in CORT in Q4 2024 and held it in 3 quarters. The position peaked at $2.37M in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Segall Bryant & Hamill reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 19,393 Corcept Therapeutics shares in Q3 2025, an estimated $1.42M.
  • Segall Bryant & Hamill first reported a position in Corcept Therapeutics in Q4 2024 and held it in 3 quarters.
  • Segall Bryant & Hamill's Corcept Therapeutics position peaked at $2.37M in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Segall Bryant & Hamill's 13F filing for Q3 2025, filed 12 Nov 2025.